Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: timolol maleate Clear all

Conditions: Glaucoma
Interventions: Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 28
States / cities: Chandler, Arizona • Duarte, California • Fullerton, California + 25 more

Conditions: Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions: timolol maleate, dorzolamide/timolol maleate fixed combination; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Wound Heal
Interventions: Timolol 0.25% Ophthalmic Solution, Standard Wound Care; Drug · Other
Lead sponsor: Keith G. LeBlanc, Jr, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more

Conditions: Glaucoma
Interventions: Brinzolamide 1% and timolol 0.5% fixed combination eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 20 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Latanoprost, Dorzolamide, Timolol; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 15
States / cities: New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more

Conditions: Glaucoma, Healthy
Interventions: Variation in eye pressure response to timolol and latanoprost treatment; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Omaha, Nebraska

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Xalacom, Xalatan, Timolol; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Phoenix, Arizona • Poway, California • Redding, California + 30 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: timolol hemihydrate, timolol maleate; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Hemangioma
Interventions: topical timolol maleate, Pulsed dye laser; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 3 Months
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Glaucoma
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Infantile Hemangiomas
Interventions: Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 8 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions: Timolol Maleate, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 3
States / cities: New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts

Search by objective public record fields.

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Assessing Cosopt Switch Patients

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Topical Timolol: a Comparison of Surgical Outcomes

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

AR-12286 in Combination With Latanoprost

Glaucoma Biomarkers

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Prevention of Esophageal Varices by Beta-Adrenergic Blockers